You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK):上藥康希諾註冊資本將增加至12.05億元
格隆匯 05-17 22:00

格隆匯5月17日丨康希諾生物-B(06185.HK)發佈公吿,2021年5月17日,公司、上海醫藥全資附屬公司上藥三維生物和上藥康希諾訂立有關於增資上藥康希諾(根據合資協議成立的合資企業)的該協議,據此,公司和上藥三維生物同意通過向上藥康希諾分別增資人民幣5.55億元及人民幣5.4989億元,將上藥康希諾的註冊資本從人民幣1億元增加至人民幣12.0489億元。

增資前,上藥康希諾由公司、上藥三維生物和產業投資基金分別持有45%、40%及15%,並因公司與產業投資基金訂立的一致行動協議成為公司的附屬公司。增資完成後,上藥康希諾由公司、上藥三維生物和產業投資基金分別持有約49.8%、49.0%及1.2%,並仍為公司的附屬公司。

根據公司、上藥三維生物與產業投資基金於2021年1月簽訂的合資協議,上藥康希諾預計主要從事疫苗及生物藥品的研究、開發及生產。鑑於Ad5-nCoV商業化後的全球需求,公司擬將上藥康希諾作為其在上海的生產基地用於Ad5-nCoV 的生產和供應,年產能不少於2億劑。本次增資項下公司和上藥三維生物擬作出的出資,預期將用於升級生產設施、聘請技術和生產人員、採購生產設備和原材料,這將使上藥康希諾能夠迅速建立其生產線並僱用足夠的有經驗的人員來生產Ad5-nCoV,從而滿足對新冠疫苗的全球需求。增資預計將增強上藥康希諾的資本結構,以滿足其建設和運營的需要。

此外,為促進Ad5-nCoV的供應並滿足Ad5-nCoV的全球需求,於本公吿日期,公司與上藥康希諾亦就公司與上藥康希諾之間的委託生產安排簽訂了一份條款清單以及一份技術許可協議,根據該等協議,上藥康希諾根據適用的法律法規和相關監管部門的批准,預計將在一定時期內為公司生產Ad5-nCoV。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account